BiotechTube
RayzeBio

RayzeBio

San Diego, United States· Est.
rayzebio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $784M

Overview

RayzeBio is a San Diego-based radiopharmaceutical company founded in 2020, specializing in targeted alpha therapies using actinium-225. The company has built a pipeline of drug candidates aimed at various solid tumors and was acquired by Bristol Myers Squibb, indicating strong validation of its platform and pipeline. RayzeBio's approach combines a proprietary targeting moiety with a potent radioactive payload to deliver precise, tumor-killing radiation while aiming to minimize damage to healthy tissues.

Oncology

Technology Platform

Targeted radiopharmaceutical platform using the alpha-emitting isotope Actinium-225 (Ac-225) conjugated to tumor-targeting vectors (peptides/antibodies) for precision cancer therapy.

Funding History

5
Total raised:$784M
IPO$311M
Series C$160M
Series D$160M
Series B$108M

Opportunities

The acquisition by Bristol Myers Squibb provides immense resources for clinical development and global commercialization.
The growing validated market for radiopharmaceuticals and the high unmet need in cancers like NETs, SCLC, and HCC present significant expansion potential.
Success with its lead asset could establish RayzeBio's Ac-225 platform as a new standard in targeted radiotherapy.

Risk Factors

Clinical failure of the lead Phase 3 program (RYZ101) is the primary risk.
The company faces intense competition from other radiopharmaceutical developers and must navigate the complex, constrained supply chain for actinium-225.
Regulatory hurdles and market adoption challenges for a novel therapeutic modality also pose significant risks.

Competitive Landscape

RayzeBio competes in the rapidly evolving radiopharmaceutical space against leaders like Novartis (with Lutathera and Pluvicto) and Bayer. It also faces competition from other companies developing alpha therapies, such as Fusion Pharmaceuticals (now part of AstraZeneca), Orano Med, and Alpha Tau Medical. Its differentiation lies in its specific focus on and expertise with Actinium-225.

More companies in Radiopharmaceuticals →More companies in United States →